Breast Group

The NCRI Breast Group brings together clinicians, scientists and patients, carers and others affected by cancer (also known as ‘consumers’), amongst many others, to coordinate the development of a strategic portfolio of research within the field of breast cancer. The group works closely with clinical research networks, funders and researchers to develop research to improve outcomes for breast cancer patients.  

The group routinely identifies priorities in breast cancer research and dynamic working groups are established to address each priority.

NCRI Breast Group strategic priorities

  • Personalised medicine and risk-adapted studies
  • Metastatic breast cancer
  • Symptom management
  • Early breast cancer clinical trials
  • Understanding the immuno-biology of breast cancer

NCRI Breast Group strategic priorities

How can I get involved?

Join the NCRI Breast Network

Group members

Mr Stuart McIntosh

Chair

Mr McIntosh is a Consultant Breast Surgeon in the Breast Unit at Belfast City Hospital. Mr McInto ...

Mr Stuart McIntosh

Chair

Mr McIntosh is a Consultant Breast Surgeon in the Breast Unit at Belfast City Hospital. Mr McIntosh has extensive experience in all aspects of breast cancer surgery, and has a particular interest in reconstruction of the breast following the surgical treatment of breast cancer, in order to achieve the best possible aesthetic outcomes for women undergoing this type of treatment.

Dr Sheeba Irshad

Deputy Chair

Sheeba Irshad is a Senior Clinical Lecturer and Breast Cancer Medical Oncologist at King’s Coll ...

Dr Sheeba Irshad

Deputy Chair

Sheeba Irshad is a Senior Clinical Lecturer and Breast Cancer Medical Oncologist at King’s College London and Guy’s & St Thomas’ NHS Trust. She specialises in researching hard to treat breast cancers, and as a CRUK-funded Clinician Scientist, she has established an independent research group focussed on understanding the immune landscape of chemotherapy resistant breast cancers. The goal is to find effective immunotherapy treatments for patients. She is the translational lead and coordinating investigator for a multi-national clinical trial platform (PHOENIX) to explore the potential interactions between DNA damage response inhibitors and immunotherapy in high-risk Triple Negative Breast Cancers. She is the chief investigator of a multi-centre “SOAP” study: Sars-Cov-2 for Cancer Patients. The research has directly contributed to changes in vaccine policy in the UK. Additionally, she is the chief investigator for the “Outlier” study investigating the immune surveillance mechanisms in “exceptional responders” of stage 4 cancers.

More from NCRI